Alvotech specializes in making biosimilars to create biologic medicines.
Alvotech is a fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines.
The company's goal is to improve patients' health and quality of life around the world by increasing access to effective therapies for various ailments.
Alvotech was established on January 1, 2013 by Róbert Wessman in Reykjavík, Gullbringusysla.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 23, 2023 | Post-IPO Equity | $137M | — | — | — | Detail |
Dec 16, 2022 | Post-IPO Debt | $70M | — | — | — | Detail |
Jun 16, 2022 | IPO | — | — | — | — | Detail |
Mar 15, 2021 | Series Unknown | $35M | — | — | — | Detail |
Oct 27, 2020 | Series Unknown | $65M | 5 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Fuji Pharma | Yes | Corporate Round |
Alvogen | — | Series Unknown |
Athos Capital | — | Series Unknown |
Aztiq Pharma | — | Series Unknown |
Baxter Ventures | — | Series Unknown |
Shinhan Capital | — | Series Unknown |
Alvotech has acquired 1 organizations. Their most recent acquisition was Baliopharm on May 19, 2016. They acquired Baliopharm for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
May 19, 2016
Baliopharm
|
Biotechnology | acquisition | — | Detail |